Company intelligence
As of September 23, 2026, Basecamp Research has raised at least $200M in equity across 2 sourced funding rounds.
Basecamp Research is an AI company developing AI-designed medicines.
Basecamp Research is a London-based company that builds AI models to design medicines, with offices and labs in Cambridge, Massachusetts.[1] Its EDEN models are trained on the Trillion Gene Atlas, a proprietary genomic dataset collected through partnerships in more than 30 countries.[1] The company is applying EDEN first to in vivo cell therapy, reprogramming a patient's cells inside the body.[1] The money will train new EDEN models and move a pipeline of designed therapeutics toward clinical development.[1] The company reported strong preclinical results but gave no timeline for starting clinical trials.[2] It also hired former Biogen executive Richard Pearce as chief business officer.[1]
Is something wrong on this page?
Basecamp Research is a biotech company, based in London.
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 23, 2026 | Series C | $140M | — | WithMenlo VenturesNvidiaNATO Innovation FundCatalio Capital ManagementTrue VenturesRockefeller Foundation | PR Newswire |
| Oct 2024 | Series B | $60M | — | — WithSingular | Yahoo Finance |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Basecamp raised a $60 million Series B led by Singular in October 2024.[2] In September 2026 it raised a $140 million Series C that valued the company at $800 million.[2],[1] S32 led the round, with participation from NVIDIA, the NATO Innovation Fund, The Rockefeller Foundation, Catalio Capital Management, Singular, True Ventures and others.[1]
AI-driven drug discovery startups keep pulling nine-figure rounds, with Basecamp Research closing an oversubscribed $140 million Series C and CellCentric raising $220 million.
Basecamp Research raised a $140 million Series C led by Bill Maris's S32, with Nvidia and Menlo Ventures' Anthology Fund among the backers, to train a new generation of its EDEN foundation models and push AI-designed therapeutics into clinical development.
In September 2026 it raised a $140 million Series C that valued the company at $800 million.[2],[1]
Basecamp raised a $60 million Series B led by Singular in October 2024.[2]
S32 led the round, with participation from NVIDIA, the NATO Innovation Fund, The Rockefeller Foundation, Catalio Capital Management, Singular, True Ventures and others.[1]
Glen Gowers is co-founder and CEO.[1]
Basecamp Research is a London-based company that builds AI models to design medicines, with offices and labs in Cambridge, Massachusetts.[1]
Basecamp Research is headquartered in London, according to prnewswire.com.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.